Edition:
United States

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

897.15INR
4:23am EDT
Change (% chg)

Rs-1.70 (-0.19%)
Prev Close
Rs898.85
Open
Rs901.00
Day's High
Rs901.85
Day's Low
Rs890.25
Volume
184,737
Avg. Vol
499,618
52-wk High
Rs994.00
52-wk Low
Rs730.00

Latest Key Developments (Source: Significant Developments)

Glenmark Pharma gets ANDA approval for fenofibrate capsules
Sunday, 9 Apr 2017 11:18pm EDT 

Glenmark Pharmaceuticals Ltd :Receives ANDA approval for fenofibrate capsules.  Full Article

Glenmark Pharma gets tentative ANDA approval from USFDA for milnacipran hydrochloride tablets
Thursday, 30 Mar 2017 11:14pm EDT 

Glenmark Pharmaceuticals Ltd :Receives tentative ANDA approval for milnacipran hydrochloride tablets.  Full Article

Glenmark Pharmaceuticals reports positive results from phase 3 trial of gsp 301
Wednesday, 29 Mar 2017 10:28am EDT 

Glenmark Pharmaceuticals Ltd : Glenmark Pharmaceuticals reports positive results from a Phase 3 trial of GSP 301, Mometasone/Olopatadine fixed-dose combination nasal spray, in seasonal allergic rhinitis . In trial treatment with GSP 301 demonstrated statistically significant and clinically meaningful improvement from baseline .All investigational treatments administered in trial were well-tolerated.  Full Article

Glenmark Pharma gets ANDA approval from USFDA for clobetasol propionate ointment
Monday, 20 Mar 2017 11:38pm EDT 

Glenmark Pharmaceuticals Ltd :Says receives ANDA approval for clobetasol propionate ointment USP, 0.05%.  Full Article

Glenmark Pharma gets tentative FDA nod for fingolimod capsules
Monday, 20 Mar 2017 12:54am EDT 

Glenmark Pharmaceuticals Ltd :Says Glenmark Pharmaceuticals receives tentative ANDA approval for Fingolimod capsules, 0.5 mg.  Full Article

Glenmark Pharma says Ankleshwar plant gets EIR issued by USFDA
Tuesday, 14 Mar 2017 11:36pm EDT 

Glenmark Pharmaceuticals Ltd :Says Ankleshwar plant has received the EIR (Establishment Inspection Report) issued by the FDA.  Full Article

Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304
Tuesday, 7 Mar 2017 10:49am EST 

Glenmark Pharmaceuticals Ltd : Glenmark Pharmaceuticals receives FDA clearance of IND for GSP 304 .Plans to initiate clinical development with a Phase 2 study of GSP 304 in subjects with mild to moderate COPD.  Full Article

Glenmark Pharmaceuticals and Evestra announce partnership agreement for generic NuvaRing
Wednesday, 1 Mar 2017 01:58pm EST 

Glenmark Pharmaceuticals Inc USA: Glenmark Pharmaceuticals And Evestra, Inc. announce partnership agreement for generic NuvaRing . Glenmark Pharmaceuticals USA and Evestra, expect to file an Abbreviated New Drug Application in fiscal 2019 . Evestra will develop this product exclusively for Glenmark for U.S. Market .Has secured exclusive marketing and distribution rights for product, for U.S. Market.  Full Article

Glenmark Pharmaceuticals Dec-qtr consol profit more than doubles
Thursday, 2 Feb 2017 02:41am EST 

Glenmark Pharmaceuticals Ltd : Glenmark Pharmaceuticals Ltd - dec-quarter consol net profit 4.77 billion rupees . Glenmark Pharmaceuticals Ltd - dec-quarter consol net sales 24.63 billion rupees . Glenmark Pharmaceuticals Ltd says overall growth for the organization has been bolstered due to the strong performance by US formulation business. . Glenmark Pharmaceuticals Ltd - consol net profit in dec quarter last year was 1.96 billion rupees as per Ind-AS; consol net sales was 17.46 billion rupees .Glenmark Pharmaceuticals Ltd consensus forecast for dec-quarter consol profit was 3.33 billion rupees.  Full Article

Glenmark Pharmaceuticals sees revenues to grow at a CAGR of 15-20 pct over next 5 years
Tuesday, 10 Jan 2017 08:27am EST 

Glenmark Pharmaceuticals Ltd : Says POC study ongoing in USA and Canada in adults with moderate-to-severe ad for GBR 830; expect to complete by q3 cy17 . Says phase 1 part 1 dose escalation study currently underway in her2+ subjects for GBR 1302 . Says GBR 1342 is expected to enter clinic in cy17 with US Ind submission planned in h1 cy17 . Says operating margin to be at 22-23 percent from fy18 onwards . Sees higher margin in fy17 on account of G-Zetia launch . Sees revenues to grow at a CAGR of 15-20% over the next 5 years . Says expected to file 9 NDA/BLA in the next decade across NME and specialty portfolio . Sees annual spend on intangible assets to be INR 2 billion on account of inlicensing of complex generics . Sees capital expenditure of INR 6-7 billion on fixed assets annually .Sees ROCE to be 18-20 pct over the next 4-5 years.  Full Article

More From Around the Web

BRIEF-Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, proposed biosimilar candidate for XOLAIR

* Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair® Source text for Eikon: Further company coverage: